Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream
NCT ID: NCT04842422
Last Updated: 2022-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
48 participants
INTERVENTIONAL
2021-04-16
2021-08-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study is to demonstrate that Aktinic Keratosis are present before they are clinically visible, i.e. in a subclinical stage. Since on the basis of the research situation, also subclinical AK can proliferate into the dermis, it is possible that with the application of Imiquimod on chronically light-exposed skin, undetected squamous cell carcinoma can be recognized and treated at the same time.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Imiquimod and Actinic Keratoses: an Observational Study
NCT01151956
Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis
NCT01413763
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
NCT01203878
Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
NCT00605176
Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)
NCT00603798
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Earliest Stage Treatment of Aktinic Keratosis
Imiquimod 3.75% Cream
Imiquimod 3.75% Cream
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Imiquimod 3.75% Cream
Imiquimod 3.75% Cream
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis: patients with chronically UV-exposed photodamaged facial skin.
* Consent by signing the ICF (Informed Consent Form)
Exclusion
* Current participation in another clinical trial
* Patients who are using topical glucocorticoids on the face.
* Known intolerance/hypersensitivity to imiquimod
* Pregnant/breastfeeding women
* Systemic disease, immunodeficiency
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Graz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitätsklinik für Dermatologie und Venerologie
Graz, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.